news PL8177 shows success as COVID-19 therapy in pre-clinical trials 24 June 2020 | By Victoria Rees (Drug Target Review) The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.
news Open source all-atom model of entire COVID-19 S protein released 23 June 2020 | By Victoria Rees (Drug Target Review) Researchers have developed a video and model-building programme for other scientists to build full-length COVID-19 S protein models.
news N terminal domain of S protein revealed as antibody target for COVID-19 23 June 2020 | By Victoria Rees (Drug Target Review) An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
news Method to convert any mouse into COVID-19 model made available to researchers 22 June 2020 | By Victoria Rees (Drug Target Review) Researchers who reported that delivering the human ACE2 protein into mouse airway cells creates COVID-19 models have released their findings to allow other scientists to make their own models.
article 3D bioprinting COVID-19 lung models for drug development 19 June 2020 | By Hannah Balfour (Drug Target Review) Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
news Biomarker suggests COVID-19 could cause brain injury in patients 19 June 2020 | By Victoria Rees (Drug Target Review) Researchers have found that a neurofilament named NfL is heightened in COVID-19 patients who require ventilator treatment, so could serve as a biomarker for the disease.
news Decoy nanoparticles show success in cell cultures as COVID-19 therapy 18 June 2020 | By Victoria Rees (Drug Target Review) Researchers have developed 'nanosponges' cloaked in lung cell membranes and macrophage membranes which they found could attract and neutralise COVID-19 in cell cultures.
news New antibody cocktail developed as potential therapy for COVID-19 17 June 2020 | By Victoria Rees (Drug Target Review) Researchers have proposed a cocktail of two antibodies which they say could provide an effective therapy for COVID-19 patients.
news “Potent” antibodies provide protection from COVID-19 in cell cultures, finds study 16 June 2020 | By Victoria Rees (Drug Target Review) Newly discovered antibodies found in the blood of recovered COVID-19 patients could provide robust protection against SARS-CoV-2, say researchers.
news COVID-19 poses threat to entire nervous system, says study 15 June 2020 | By Victoria Rees (Drug Target Review) Following an analysis of scientific literature, researchers say that COVID-19 may affect the entire nervous system, including the brain, spinal cord, nerves and muscles.
news Link identified between COVID-19 and onset of diabetes 15 June 2020 | By Victoria Rees (Drug Target Review) New research indicates COVID-19 could trigger the development of diabetes in healthy people, prompting experts to establish a registry for COVID-19 and diabetes data.
news Naphthalene-based PLpro inhibitors show potential as COVID-19 therapeutics 12 June 2020 | By Victoria Rees (Drug Target Review) A group of small molecules called naphthalene-based PLpro inhibitors have been shown to block the activity of a SARS-CoV-2 protein, demonstrating potential as COVID-19 therapeutics.
article What immuno-oncology research can tell us about COVID-19 11 June 2020 | By Dr Jing Watnick (Vigeo Therapeutics) Dr Jing Watnick discusses how lessons learnt from cancer immunotherapy treatments could be applied to the development of COVID-19 therapies.
news Rod-shaped microparticles could improve immune system response to COVID-19 11 June 2020 | By Victoria Rees (Drug Target Review) Researchers have suggested that neutrophils, which contribute to the development of ARDS in COVID-19 patients, could be diverted from the lungs by rod-shaped particles in a new form of treatment.
news Protease inhibitors could be highly effective against SARS-CoV-2 10 June 2020 | By Hannah Balfour (Drug Target Review) Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
